SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
- PMID: 36877973
- DOI: 10.7326/J23-0002
SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
Abstract
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801. 36351458.
Comment on
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources